Research and Markets: Commercializing Breast Cancer Drugs: The 2012 Faster Route to Consider Your Options and Position of Others

Research and Markets has announced the addition of the "Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others" report to their offering. Buy Aldactone (Spironolactone) pills online without prescription

“Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others”

This report will excel your competitive awareness and decrease your decision making time in managing breast cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
This report comprises defined and up to date development strategies for 470 breast cancer drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer.
BioSeeker has applied its unique drug assessment methodology to stratify the breast cancer drug pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of breast cancer drugs is split between the approximately one third which have unique drug target strategies and the other two thirds which have head-to-head target competing drugs in 61 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the breast cancer drugs in general.
- Nine out of every ten drug target strategies in Phase II and three out of every four in Phase III development are new to breast cancer drugs.
- The greatest number of new target strategies are found in Phase II (35%) and Preclinical (17%) development.
- Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of breast cancer drugs, which represent almost 80% of the entire pipeline.
- Besides Reformulated drugs, it is Cell therapies, Peptides and Antibodies based breast cancer drugs that have the highest cross-over of drug target strategies with other compound strategies.
- The highest number of described drug target strategies of breast cancer drugs belongs to Pfizer, AstraZeneca and Hoffmann-La Roche.
Companies Mentioned:
- A&G Pharmaceutical
- Abbott
- Bayer
- Bristol-Myers Squibb
- Cytokinetics
- Eli Lilly
- Formula Pharmaceuticals
- Fresenius
- Galectin Therapeutics
- Harbor BioSciences
- Idera Pharmaceuticals
- Johnson & Johnson
- Kiadis
- Lorus Therapeutics
- MacroGenics
- Novartis
- Oasmia
- OncoGenex Pharmaceuticals
- Raptor Pharmaceutical
- Receptor BioLogix
- Schering-Plough
- Takeda
- Trion Pharma
- Vaccinex
- Wyeth
- Xoma
- Yakult Honsha
- Zydus Cadila